Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase

Protein Science

Volumn 15, Issue 8, 2006, Pages 1842-1848

  Addlagatta, Anthony ^a   Matthews, Brian W ^a  

^a UNIVERSITY OF OREGON   (United States)

Author keywords

Angiogenesis; Cancer; Fumagillin; Methionine aminopeptidase

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLIN; HISTIDINE; METHIONINE; METHIONINE AMINOPEPTIDASE1; METHIONINE AMINOPEPTIDASE2; METHIONYL AMINOPEPTIDASE; OVALICIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; COMPARATIVE STUDY; CRYSTAL STRUCTURE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESIDUE ANALYSIS; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; AMINOPEPTIDASES; ANGIOGENESIS INHIBITORS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; GLYCOPROTEINS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SESQUITERPENES;

EID: 33746496094     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.062278006     Document Type: Article

References (26)

1. Addlagatta, A., Hu, X., Liu, J.O., and Matthews, B.W. 2005. Structural basis for the functional differences between Type I and Type II human methionine aminopeptidases. Biochemistry 44: 14741-14749.
2. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
3. Bhargava, P., Marshall, J.L., Rizvi, N., Dahut, W., Yoe, J., Figuera, M., Phipps, K., Ong, V.S., Kato, A., and Hawkins, M.J. 1999. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5: 1989-1995.
4. Brdlik, C.M. and Crews, C.M. 2004. A single amino acid residue defines the difference in ovalicin sensitivity between Type I and II methionine aminopeptidases. J. Biol. Chem. 279: 9475-9480.
5. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905-921.
6. Cosper, N.J., D'Souza, V.M., Scott, R.A., and Holz, R.C. 2001. Structural evidence that the methionyl aminopeptidase from Escherichia coli is a mononuclear metalloprotease. Biochemistry 40: 13302-13309.
7. D'Souza, V.M., Brown, R.S., Bennett, B., and Holz, R.C. 2005. Characterization of the active site and insight into the binding mode of the antiangiogenesis agent fumagillin to the manganese(II) loaded methionyl aminopeptidase from Escherichia coli. J. Biol. Inorg. Chem. 10: 41-50.
8. Folkman, J. 1971. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285: 1182-1186.
9. Griffith, E.C., Su, Z., Turk, B.E., Chen, S., Chang, Y.H., Wu, Z., Biemann, K., and Liu, J.O. 1997. Methionine aminopeptidase (Type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4: 461-471.
10. Herbst, R.S., Madden, T.L., Tran, H.T., Blumenschein Jr., G.R., Meyers, C.A., Seabrooke, L.F., Khuri, F.R., Puduvalli, V.K., Allgood, V., Fritsche Jr., H.A., et al. 2002. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small cell lung cancer. J. Clin. Oncol. 20: 4440-4447.
11. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557.
12. Kissinger, C.R., Gehlhaar, D.K., and Fogel, D.B. 1999. Rapid automated molecular replacement by evolutionary search. Acta Crystallogr. D Biol. Crystallogr. 55: 484-491.
13. Klein, C.D., Schiffmann, R., Folkers, G., Piana, S., and Rothlisberger, U. 2003. Protonation states of methionine aminopeptidase and their relevance for inhibitor binding and catalytic activity. J. Biol. Chem. 278: 47862-47867.
14. Kleywegt, G.J. and Jones, T.A. 1998. Databases in protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 54: 1119-1131.
15. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. 1994. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer 69: 212-216.
16. Liu, S., Widom, J., Kemp, C.W., Crews, C.M., and Clardy, J. 1998. Structure of human methionine aminopeptidase 2 complexed with fumagillin. Science 282: 1324-1327.
17. Logothetis, C.J., Wu, K.K., Finn, L.D., Daliani, D., Figg, W., Ghaddar, H., and Gutterman, J.U. 2001. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen independent prostate cancer. Clin. Cancer Res. 7: 1198-1203.
18. Lowther, W.T., McMillen, D.A., Orville, A.M., and Matthews, B.W. 1998. The anti-angiogenic agent fumagillin covalently modifies a conserved active site histidine in the Escherichia coli methionine aminopeptidase. Proc. Natl. Acad. Sci. 95: 12153-12157.
19. Otwinowski, Z. and Minor, W. 1997. Processing of X-ray diffraction data collected in oscillation mode. In Macromolecular crystallography, part A (eds. C. Carter and R. Sweet), Vol. 276, pp. 307-326. Academic Press, New York.
20. Sheldrick, G.M. and Schneider, T.R. 1997. SHELXL: High resolution refinement. Methods Enzymol. 277: 319-343.
21. Sin, N., Meng, L., Wang, M.Q., Wen, J.J., Bornmann, W.G., and Crews, C.M. 1997. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. 94: 6099-6103.
22. Stadler, W.M., Kuzel, T., Shapiro, C., Sosman, J., Clark, J., and Vogelzang, N.J. 1999. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17: 2541-2545.
23. Yamamoto, T., Sudo, K., and Fujita, T. 1994. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res. 14: 1-3.
24. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. 1993a. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53: 5233-5236.
25. Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., and Fujita, T. 1993b. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O (chloroacetyl carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res. 53: 4262-4267.
26. Zhou, G., Tsai, C.W., and Liu, J.O. 2003. Fumagalone, a reversible inhibitor of Type 2 methionine aminopeptidase and angiogenesis. J. Med. Chem. 46: 3452-3454.